# A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa

> **NCT07547813** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Almirall, S.A.** · enrollment: 50 (estimated)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** LAD328
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07547813
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-02
- **Final completion:** 2027-04
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07547813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07547813, "A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07547813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*